Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3164 Automatized hepatic tumor volume analysis of neuroendocrine liver metastases by Gd-EOB MRI - A deep learning model to support multidisciplinary cancer conference decision making

Introduction: Rapid quantification of liver metastasis for diagnosis and follow-up is an unmet medical need in patients with secondary liver malignancies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Xin S, Hartenstein A, Auer T, Dräger F,

Keywords: liver metastases, automatised 3D quantification, deep learning, hepatic tumor load, response evaluation, MRI,

#1011 Predictive Factors for Progression Free Survival (PFS) in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNET) Treated with Sunitinib

Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Jiménez-Fonseca P, Carmona A, Solis M, Faez L, Ruiz A,

Keywords: Sunitinib, pancreatic neuroendocrine tumor, prior treatment, predictive factor,

#486 Benefit of Octreotide LAR in Patients with Neuroendocrine Midgut Tumors Who Previously Progressed on Placebo Therapy: Two Cases From the PROMID Study

Introduction: In the phase IIIb PROMID study, patients with advanced low-/intermediate-grade midgut neuroendocrine tumors (NET) received Octreotide LAR (O; 30 mg IM q28d) or placebo (P). Median time to tumor progression (TTP) was increased 8.3 mo in patients receiving O v. P (HR=0.34; 95% CI, 0.20-0.59; P

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Rinke A,

Keywords: somatostatin analog, neuroendocrine, Octreotide, time to progression,